Clasp Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Maryland, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1450 Research Blvd 120, Rockville, Maryl...Website
www.clasptx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
2
2
1
1
1
About Clasp Therapeutics
Clasp Therapeutics is focused on advancing immuno-oncology through the development of next-generation T cell engagers that target specific cancer mutations. Their innovative approach aims to enhance the precision of cancer treatments by enabling the immune system to identify and destroy hard-to-treat tumors. The company is dedicated to creating off-the-shelf precision immunotherapies that can be tailored to individual patients, thereby expanding treatment options for various cancer types. Clasp Therapeutics is committed to translating cutting-edge research into meaningful medicines that improve patient outcomes.Explore more
Popular SearchesClasp TherapeuticsSIC Code 87,873NAICS Code 54,541Show moreClasp Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Clasp Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Clasp Therapeutics is spiking on competitors!
Earning: See what the market has to say on Clasp Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once Clasp Therapeutics has new funding data
Product Launch: Get notified when Clasp Therapeutics launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Clasp Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Clasp Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Clasp Therapeutics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Clasp Therapeutics
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined Clasp Therapeutics as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
Clasp Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Clasp Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Clasp Therapeutics.
Clasp Therapeutics financials insights
Gather financial insights about Clasp Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Other Financing Round
$150M
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Event
Events, Engineering, Sales, Bioengineering, Laboratory Operations, Pharmaceuticals, Field /Outside Sales, Clinical Operations, Field Marketing, Operations
Person-Based
Funding
Funding
Clasp Therapeutics News & Media
Clasp Therapeutics Presents Comprehensive Preclinical Data Validating First-in-Class Precision T Cell Engager Against p53 Mutant Solid Tumors at SITC Annual Meeting
CAMBRIDGE, MA. & ROCKVILLE, MD.--(BUSINESS WIRE)--Clasp Therapeutics, a biotechnology company bringing unparalleled precision to immuno-oncology using next-generation TCEs, today announced new data validating the potential of its lead program, CLSP-1025. CLSP-1025 is a half-life extended TCE targeting cancer cells expressing the p53R175H mutant peptide presented by HLA-A*02:01. Data demonstrating the therapeutic potential of CLSP-1025 will be presented at the Society for Immunotherapy of CancerClasp Therapeutics to Present Preclinical Data Evaluating Novel T Cell Engager Targeting p53 Mutant Solid Tumors
CAMBRIDGE, MA. & ROCKVILLE, MD.--(BUSINESS WIRE)--Clasp Therapeutics, a biotechnology company bringing unparalleled precision to immuno-oncology using next-generation T cell engagers (TCEs), today announced it will present comprehensive preclinical data demonstrating the selectivity and activity of CLSP-1025, a TCE targeting a common p53 mutation, at the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC), being held November 8 - 10, 2024 in Houston, Texas and virtually. PreseClasp Therapeutics Grabs $150M Series A Funding
ROCKVILLE, MD, Clasp Therapeutics, a biotechnology company, has raised $150 million in financing.
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Clasp Therapeutics
Sign Up For FreeTo access detailed company insights
Clasp Therapeutics is focused on advancing immuno-oncology through the development of next-generation T cell engagers that target specific cancer mutations. Their innovative approach aims to enhance the precision of cancer treatments by enabling the immune system to identify and destroy hard-to-treat tumors. The company is dedicated to creating off... Read More
